Physician profile
Leslie E Barr
NPI 1003140963
$3,243.50
in general payments reported to CMS, 2019-2025
30 companies · $710 in 2025
The $710 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $56.92 · 2021: $321 · 2022: $587 · 2023: $533 · 2024: $781 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $539.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $490.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $274.31 | 2019-2024 | Prolia, Evenity, Repatha |
| Abbott Laboratories | $250.39 | 2021-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.58 | 2021-2024 | Jardiance |
| Daiichi Sankyo INC. | $143.06 | 2021-2024 | Injectafer |
| Pfizer INC. | $139.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.64 | 2020-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $125.86 | 2021-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $121.16 | 2019-2025 | Capvaxive, Vaxneuvance, Gardasil |
| Dexcom, INC. | $110.03 | 2022-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $106.27 | 2022-2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $102.10 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.39 | 2022 | |
| Pharmacosmos Therapeutics INC. | $48.09 | 2025 | Monoferric |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.42 | 2022-2023 | Eliquis |
| Boston Scientific Corporation | $39.81 | 2024 | Wavewriter Alpha Prime 16 |
| Gilead Sciences, INC. | $39.22 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.94 | 2023 | |
| Abbvie INC. | $37.67 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.64 | 2025 | Caplyta |
| Lundbeck LLC | $35.53 | 2023-2025 | Rexulti |
| Medtronic, INC. | $32.90 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.76 | 2021 | |
| Organon LLC | $25.24 | 2023-2025 | Jada System, Nexplanon |
| Eisai INC. | $18.19 | 2022 | |
| Astellas Pharma US INC | $16.97 | 2020 | |
| Mylan Specialty L.P. | $16.89 | 2024 | Yupelri |
| Exact Sciences Corporation | $14.93 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $14.02 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.